Shares of dialysis company Fresenius Medical Care dropped by 7.8% after the German healthcare group Fresenius SE decided to sell a portion of its ownership in the firm.
FMS, MASI, and VCYT from the Zacks Medical Instruments sector are good investment options due to their use of genAI, strategic growth, and solid financial health. However, challenges like geopolitical tensions and problems with wages and supplies could affect their future performance.
FMS' results for the fourth quarter highlight impressive performance in different areas and also give a forecast for revenue growth and operating income for the full year 2025.
Fresenius Medical Care achieved a 4% organic revenue growth, mainly due to improvements in Care Enablement and Care Delivery. The company also reported a significant increase in operating income and net income, while reducing its financial leverage ratio. Looking ahead, they expect strong earnings growth in 2025 and plan to raise dividends by 21%.
Fresenius Medical Care, the biggest dialysis company in the world, announced its fourth quarter results on Tuesday, which were a bit better than what the market expected. They mentioned good progress in both their care delivery and care enablement areas.
Fresenius Medical Care is a top company in kidney care worldwide, experiencing notable growth with an 18.5% rise since my previous article. The company is reasonably priced, with a price-to-earnings ratio of under 18.5 and a fair value estimate of at least $34 per share. While there are risks related to US healthcare politics and technology changes, the company's diverse offerings and home-care approach are significant advantages.
Fresenius (FMS) has received a Zacks Rank #1 (Strong Buy) upgrade, indicating increased confidence in the company's potential earnings. This could lead to a rise in the stock price soon.
On January 7, 2024, PRMB, FMS, and RBA were included in the Zacks Rank #1 (Strong Buy) list of income stocks.
On December 27, 2024, PAYO, TTDKY, and FMS were included in the Zacks Rank #1 (Strong Buy) list of momentum stocks.
BAD HOMBURG, Germany, Dec. 20, 2024 /PRNewswire/ -- Fresenius Medical Care (FME), a top provider of products and services for kidney disease, will rejoin the DAX 40, Germany's main stock index, starting December 27, 2024. This index tracks the performance of the 40 largest publicly traded companies on the Frankfurt Stock Exchange and represents about 80 percent of the market value of listed companies in Germany.